

PRODUCT INFORMATION



T5601640

Item No. 22140

CAS Registry No.: 924473-59-6

Formal Name: 3-methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-5-isoxazolecarboxamide

Synonym: T56-LIMKi, T56-LIM Kinase Inhibitor

MF: C₁₉H₁₄F₃N₃O₃

FW: 389.3


Purity: ≥98%

UV/Vis.: λ_{max}: 210, 233, 273 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

T5601640 is supplied as a crystalline solid. A stock solution may be made by dissolving the T5601640 in the solvent of choice, which should be purged with an inert gas. T5601640 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of T5601640 in these solvents is approximately 20 and 30 mg/ml, respectively.

T5601640 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, T5601640 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. T5601640 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

T5601640 is an inhibitor of LIM kinase 2 (LIMK2) that inhibits LIMK2-mediated cofilin phosphorylation.¹ It reduces the levels of phosphorylated cofilin (p-cofilin) in mouse embryonic fibroblasts (MEF) lacking neurofibromin (Nf1^{-/-}; IC₅₀ = 30 μM), which normally have high levels of p-cofilin. T5601640 (50 μM) decreases actin stress fiber formation, inhibits cell migration, and inhibits colony formation of Nf1^{-/-} MEF cells. It inhibits proliferation of ST88-14, U87, and PANC-1 cells with IC₅₀ values of 18.3, 7.4, and 35.2 μM, respectively, and also decreases p-cofilin levels by 20, 24, and 46%, respectively.² Oral gavage administration of T5601640 (60 mg/kg) decreases tumor volume and cofilin phosphorylation in a PANC-1 nude mouse xenograft model.

References

1. Mashiach-Farkash, E., Rak, R., Elad-Sfadia, G., et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. *Oncotarget* **3**(6), 629-639 (2012).
2. Rak, R., Haklai, R., Elad-Tzfadia, G., et al. Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. *Oncoscience* **1**(1), 39-48 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM